AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-06-12	0.8900 €	+0.23%	169,645
26-06-11	0.8880 €	-2.42%	206,532
26-06-10	0.9100 €	+1.79%	200,138
26-06-09	0.8940 €	+1.59%	186,613
26-06-08	0.8800 €	-3.30%	433,362

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-06-12 am EDT			5-day change	1st Jan Change
0.8900 ^EUR	+0.23%		-2.20%	-42.06%

Jun. 10	AB Science presents new data on Masitinib
May. 17	AB Science S.A. announced that it has received $2.989368 million in funding	CI

Market Cap	68.12M 78.87M 62.77M 58.76M 110M 7.5B 112M 741M 289M 3.65B 296M 290M 12.63B	P/E Ratio 2025 *	-	P/E Ratio 2026 *	-
Enterprise Value	68.12M 78.87M 62.77M 58.76M 110M 7.5B 112M 741M 289M 3.65B 296M 290M 12.63B	EV / Sales 2025	95.4x	EV / Sales 2026 *	56.8x
Free-Float	67.54%	Yield 2025 *	-	Yield 2026 *	-

Jun. 10	AB Science presents new data on Masitinib
May. 17	AB Science S.A. announced that it has received $2.989368 million in funding	CI
May. 13	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
May. 03	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
Apr. 29	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
Apr. 29	AB Science announces successful capital increase
Apr. 28	Air Liquide, Nexans, AB Science... stocks to watch today in Paris
Apr. 28	AB Science Reaches Maturity Extension Deal with Lenders	MT
Apr. 27	Vinci, Lumibird, SergeFerrari... stocks to watch tomorrow in Paris
Apr. 27	AB Science announces major agreement with creditors
Apr. 27	AB Science SA Announces Final Agreement on Renegotiation of Repayment Terms of Loans With Financial Creditors	CI
Apr. 21	Thales, Vivendi, Mercialys, GTT... stocks to watch today in Paris
Apr. 21	Positive data for AB Science's masitinib published on medRxiv

Jun. 09	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS	GL
Jun. 02	AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share	GL
May. 26	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of EUR4.00 per share	AQ
May. 25	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share	GL
May. 13	AB Science : Annual financial results as of 31 December, 2025	PU

AB Science Stock

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

Jun. 10	Bourse : Airbus veut rebondir sur le SCAF, Legrand se renforce, le marché attend Oracle
Jun. 10	AB Science présente de nouvelles données sur son Masitinib
Jun. 10	Ça ne respire pas la sérénité à Wall Street
Jun. 09	AB Science présentera, lors du congrès annuel 2026 de l'ENCALS, les données de survie issues du programme clinique du masitinib dans la SLA
Jun. 02	AB Science : Stonegate Capital Partners actualise sa couverture de l'action AB Science avec un objectif de cours de 4,25 EUR par action

1 day	+0.23%
1 week	-2.20%
Current month	-7.68%
1 month	-4.51%
3 months	-27.05%
6 months	-27.05%
Current year	-42.06%

1 week	0.87	0.92
1 month	0.87	1.04
Current year	0.87	1.61
1 year	0.87	1.73
3 years	0.77	4.94
5 years	0.77	16.68
10 years	0.77	21.75

Manager	Title	Age	Since
Alain Moussy CEO	Chief Executive Officer	-	2001-07-10
Laurent Guy DFI	Director of Finance/CFO	-	2009-11-19
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	2018-03-31

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	2001-07-10
Patrick Moussy BRD	Director/Board Member	-	2011-09-19
Cécile de Guillebon BRD	Director/Board Member	64	2021-06-26

Date	Insider	Type	Main position	Quantity	% Market Cap.
May. 19	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
21-02-08	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
21-02-01	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+0.23%	-2.20%	-23.93%	-79.68%	78.87M
MERCK & CO., INC.	-1.42%	-1.44%	+45.70%	+8.24%	294B
MERCK KGAA	-1.59%	-2.63%	+16.07%	-20.92%	67.08B
HALOZYME THERAPEUTICS, INC.	-1.74%	-2.84%	+28.75%	+105.32%	8.24B
KYOWA KIRIN CO., LTD.	-1.15%	+4.87%	-3.58%	-12.17%	7.84B
SK BIOPHARMACEUTICALS CO., LTD.	-0.68%	-0.23%	-2.66%	+8.52%	4.54B
YUHAN CORPORATION	+1.05%	-0.39%	-27.51%	+33.10%	3.8B
BETTA PHARMACEUTICALS CO., LTD.	+2.01%	+10.19%	-14.95%	+8.11%	3.35B
SUPERNUS PHARMACEUTICALS, INC.	-2.50%	-0.76%	+38.65%	+31.12%	2.58B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+3.11%	+1.30%	+5.67%	-22.84%	1.98B
Average	-0.27%	+2.34%	+6.22%	+5.88%	39.35B
Weighted average by Cap.	-1.37%	-1.24%	+37.27%	+5.11%

	2025	2026 *
Net sales	1.1M 1.27M 1.01M 949K 1.78M 121M 1.81M 11.97M 4.67M 58.92M 4.78M 4.68M 204M	1.2M 1.39M 1.11M 1.04M 1.94M 132M 1.97M 13.06M 5.09M 64.28M 5.21M 5.1M 223M
Net income	-	-
Net Debt	-	-